A Comprehensive Pharmacological and Clinical Review of Policresulen and Dibucaine Hydrochloride

1.0 Executive Summary & Therapeutic Overview

1.1 Introduction to the Combination Therapy

The combination of Policresulen and Dibucaine hydrochloride is a topical therapeutic agent formulated for the treatment of localized anorectal and gynecological conditions.[1] This product leverages a synergistic mechanism, uniting the distinct pharmacological actions of its two active pharmaceutical ingredients. Policresulen contributes antiseptic, hemostatic, and tissue-regenerating properties, while Dibucaine hydrochloride provides potent local anesthetic effects to alleviate pain and pruritus.[1] The primary clinical indications for this combination therapy include the management of hemorrhoids (piles), particularly those associated with inflammation and bleeding, and anal fissures.[3] It is available in formulations such as rectal ointments and suppositories to facilitate direct application to the affected mucosal tissues.[2]

1.2 Therapeutic Rationale and Clinical Positioning

The therapeutic rationale for combining Policresulen and Dibucaine hydrochloride lies in its multi-modal approach to treating complex local pathologies. Conditions such as hemorrhoidal disease present with a constellation of symptoms, including pain, itching, inflammation, and bleeding.[1] A single-agent therapy may not adequately address all these facets. Dibucaine hydrochloride, as a potent local anesthetic, directly targets the sensory symptoms of pain and itching by blocking nerve signal transmission, offering rapid symptomatic relief that can improve patient comfort and compliance.[1] Concurrently, Policresulen addresses the underlying tissue pathology. Its unique chemical properties enable it to stop bleeding, prevent secondary infection, and selectively remove necrotic or damaged tissue, thereby creating an environment conducive to healing and tissue regeneration.[2] This dual-action strategy, which provides both immediate comfort and promotes resolution of the underlying lesion, positions the product as a comprehensive topical treatment for specific, localized conditions, distinguishing it from systemic therapeutic options.

2.0 Policresulen: A Detailed Monograph

2.1 Chemical Profile and Physicochemical Properties

Policresulen is a complex polymeric substance with unique chemical characteristics that are central to its therapeutic action.

Chemical Identity and Structure

Policresulen is chemically defined as the polycondensation product of meta-cresolsulfonic acid and formaldehyde.[9] It belongs to the class of organosulfur compounds and is specifically categorized as an aromatic sulfonic acid derivative.[10] Its formal chemical name is 2-Hydroxy-3,5-bis[(4-hydroxy-2-methyl-5-sulfophenyl)methyl]-4-methylbenzenesulfonic acid.[13] Due to its polymeric nature, its molecular formula is variably represented, for instance as

, , or , which results in a variable molar mass rather than a fixed molecular weight.[9] This structural variability, with inconsistent chain lengths and molecular weights across batches, presents significant challenges for analytical characterization and manufacturing standardization. Such complexity may be a contributing factor to its fragmented regulatory approval status, particularly in jurisdictions like the United States where stringent requirements for active pharmaceutical ingredient (API) characterization and batch-to-batch consistency are paramount for new drug applications.[9]

Physicochemical Properties

The key physicochemical properties of Policresulen are summarized in Table 1. It is typically supplied as a brown liquid formulation with a distinct phenol-like odor.[13] Its most critical property is its extremely high acidity, with a pH value of less than 1, which underpins its mechanism of action.[13] Safety data sheets highlight its hazardous nature, classifying it as corrosive to skin, the respiratory system, and capable of causing serious eye damage.[13] Furthermore, it reacts with many metals to liberate hydrogen gas, a highly flammable substance that can form explosive mixtures with air, necessitating careful storage and handling procedures.[13]

Table 1: Physicochemical Properties of Policresulen
Property	Value / Description
Chemical Name	2-Hydroxy-3,5-bis[(4-hydroxy-2-methyl-5-sulfophenyl)methyl]-4-methylbenzenesulfonic acid 13
CAS Number	101418-00-2 9
PubChem CID	3050404 9
Molecular Formula	Variable; e.g.,  9
Molar Mass	Variable 9
Physical State	Liquid (in formulation) 14
Color	Brown 13
Odor	Phenol-like 13
pH	13
Water Solubility	Partly miscible 14
Density	Approx. 1.135 g/cm³ 14
Corrosivity	Corrosive to skin, eyes, and respiratory system 13
Reactivity	Reacts with many metals to liberate hydrogen gas; can react with strong oxidizing agents 13

2.2 Pharmacodynamics and Mechanism of Action

Policresulen exerts its therapeutic effects through a multi-faceted mechanism of action that is primarily driven by its high acidity.

• Selective Coagulative Necrosis: The principal mechanism is the induction of coagulative necrosis. Its strong acidic nature (pH < 1) causes denaturation and precipitation of cellular proteins. This effect is selective for necrotic and pathologically altered tissues, while healthy, intact epithelium is largely spared.[2] The coagulated pathological tissue is subsequently shed from the lesion, a process that functions as a form of chemical debridement.[11]
• Antiseptic and Antimicrobial Action: The low pH environment created upon application is strongly antimicrobial, inhibiting the growth of a broad spectrum of pathogens. It is effective against common Gram-positive and Gram-negative bacteria, fungi such as Candida albicans, and certain viruses.[11] This action is achieved through the disruption of microbial cell membranes and impairment of metabolic functions.[11] Notably, it is effective against gynecological pathogens like Gardnerella vaginalis and Trichomonas while not adversely affecting the normal protective Doderlein vaginal flora.[24]
• Hemostatic Action: Policresulen effectively controls local bleeding through two distinct actions. It causes coagulation of blood proteins at the wound surface and induces constriction of the muscular fibers in the walls of small blood vessels, leading to vasoconstriction.[2] This results in the formation of a protective film of denatured protein over the bleeding area, promptly arresting hemorrhage.[2]
• Promotion of Tissue Regeneration: By facilitating the rapid cleansing and removal of necrotic tissue and stimulating a reactive hyperemia (increased blood flow) in the treated area, Policresulen accelerates the natural processes of wound healing and re-epithelialization.[2]

2.3 Clinical Applications (Monotherapy)

The use of Policresulen as a standalone agent has a long history, particularly in gynecology, where it has been used since the 1950s.[9]

• Gynecology: It is widely indicated for various gynecological conditions, including cervical erosion, cervicitis, and different forms of vaginitis (bacterial, trichomonal, and fungal).[10] It is formulated as vaginal suppositories (e.g., Albothyl 90mg) and concentrated solutions for direct application by a healthcare professional.[10]
• Dermatology and Proctology: Its application has expanded to include the treatment of other mucous membrane and skin lesions, such as anal fissures and hemorrhoids.[9]
• Stomatology: In some countries, it is used for the topical treatment of oral ulcers, including canker sores (aphthous ulcers).[9] However, its high acidity poses a risk, and reports of oral mucosal burns from improper use underscore the need for careful application.[30]

3.0 Dibucaine Hydrochloride: A Detailed Monograph

3.1 Chemical Profile and Physicochemical Properties

Dibucaine hydrochloride is a well-characterized small molecule with potent anesthetic properties.

Chemical Identity and Structure

The formal chemical name for Dibucaine hydrochloride is 2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide hydrochloride.[31] It is also commonly known by its synonym, Cinchocaine hydrochloride.[32] Its molecular formula is

, corresponding to a molecular weight of approximately 379.92 g/mol.[31]

Physicochemical Properties

Dibucaine hydrochloride is a white to light yellow, odorless crystalline powder that is known to be hygroscopic (absorbs moisture from the air).[31] It exhibits high solubility in water, alcohol, and acetone.[31] Its stability is affected by exposure to light and air, requiring appropriate storage conditions.[32] The key physicochemical properties are consolidated in Table 2.

Table 2: Physicochemical Properties of Dibucaine Hydrochloride
Property	Value / Description
Chemical Name	2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide hydrochloride 31
Synonyms	Cinchocaine hydrochloride 34
CAS Number	61-12-1 31
PubChem CID	521951 33
Molecular Formula	31
Molecular Weight	379.92 g/mol 31
Physical Appearance	White to light yellow powder or hygroscopic crystals 31
Odor	Odorless 40
Melting Point	97-101 °C 32
Solubility	Freely soluble in water, alcohol, acetone, chloroform 31
Stability	Sensitive to light; air sensitive; hygroscopic 32
pKa (Strongest Basic)	9.04 38
logP	3.79 38

3.2 Pharmacodynamics and Mechanism of Action

Dibucaine is classified as a potent, long-acting, amide-type topical local anesthetic.[7] It is regarded as one of the most potent and also most toxic agents in its class, which has historically limited its systemic applications.[40]

Its mechanism of action is characteristic of local anesthetics. It reversibly blocks the generation and conduction of nerve impulses by stabilizing the neuronal membrane. This is achieved by inhibiting the transient increase in sodium permeability through voltage-gated sodium channels that is required for an action potential to occur.[3] By preventing depolarization, it effectively "deadens" cutaneous nerve endings, thereby blocking the transmission of pain and itch signals to the brain.[7] Specific molecular targets identified include various sodium channel subunits, such as SCN1A, SCN2A, SCN3A, SCN5A, and SCN10A.[36]

3.3 Clinical Applications (Monotherapy)

As a single agent, Dibucaine is primarily used for surface anesthesia. It is widely available over-the-counter (OTC) in many regions, most commonly as a 1% topical ointment.[8] Its approved uses are for the temporary symptomatic relief of pain and itching arising from minor skin conditions, including sunburn, minor burns, insect bites or stings, minor cuts, and scratches.[7] It is also indicated for anorectal conditions such as hemorrhoids to alleviate local pain and itching.[42] Due to its high systemic toxicity, its parenteral use has been largely restricted to spinal anesthesia in controlled clinical settings.[40]

4.0 The Combination Product: Policresulen/Dibucaine Hydrochloride

4.1 Formulation, Dosage Forms, and Administration

The combination of Policresulen and Dibucaine hydrochloride is marketed in topical formulations designed for direct application to anorectal or gynecological mucosa.

• Dosage Forms: The product is commercially available as a rectal ointment and as suppositories.[2]
• Composition: A common and representative formulation for the ointment contains 50 mg of Policresulen and 10 mg of Dibucaine hydrochloride (also referred to as cinchocaine hydrochloride) per gram of ointment.[2] The suppositories are typically formulated to contain 100 mg of Policresulen and 2.5 mg of Dibucaine hydrochloride per unit.[53]
• Administration Guidelines: For anorectal conditions, the ointment is applied to the affected area 2 to 3 times per day. Application is recommended after a bowel movement to maximize contact time and efficacy. An applicator is often supplied with the ointment to facilitate controlled internal application into the anal canal.[2] Suppositories are designed for internal hemorrhoids and are inserted into the rectum 2 to 3 times daily, also preferably after defecation.[55]

4.2 Approved Medical Uses and Clinical Efficacy

The primary approved indication for the combination product is the topical treatment of anorectal disorders.[1] This includes internal and external hemorrhoids, especially those complicated by inflammatory symptoms or superficial bleeding, as well as anal fissures and rhagades.[1] The product is promoted as a comprehensive treatment that quickly eliminates bleeding, oozing, pain, and itching, while also preventing inflammation and stimulating the regeneration of affected tissue.[2]

4.3 Critical Review of Clinical Evidence

The clinical evidence supporting the efficacy of the Policresulen/Dibucaine hydrochloride combination is mixed, with different study designs yielding conflicting results. A summary of the key clinical trials is presented in Table 3.

A large analytical review of seven multicenter studies, encompassing a total of 2,287 patients with various hemorrhoidal pathologies, provides the main body of supportive evidence.[23] In this meta-analysis, investigators rated the therapeutic outcome as "highly satisfactory" in 83.2% of patients, with a similar patient-reported satisfaction rate of 82.2%. The review concluded that the combination was effective for a range of indications, including bleeding hemorrhoids, anal fissures, anal eczema, and post-operative wound care after proctological surgery.[23]

In stark contrast, a more rigorously designed prospective, double-blinded, placebo-controlled study involving 43 patients specifically evaluated the product's efficacy for managing pain after open hemorrhoidectomy.[26] This trial found no statistically significant reduction in pain, as measured by a visual analogue scale (VAS), at any measured time point up to 15 days post-surgery. The pain scores in the group receiving the active ointment were not different from those in the placebo ointment group or a control group receiving only standard oral analgesics.[26]

This discrepancy in findings suggests that the therapeutic utility of the combination is highly dependent on the clinical context. The large meta-analysis supports its use for the management of chronic or subacute symptoms of hemorrhoidal disease, where factors like mild bleeding, inflammation, and discomfort are prominent. In this setting, the product's multi-modal action appears to be beneficial and leads to high patient satisfaction. However, the negative result from the rigorous controlled trial indicates that the product is likely ineffective for managing the severe, acute pain characteristic of the postoperative period following hemorrhoidectomy. The intensity of surgical pain may overwhelm the analgesic capacity of a topical anesthetic like Dibucaine, or its effect may be clinically insignificant when used in conjunction with the standard regimen of systemic oral analgesics given to all patients in the trial. This distinction is critical for clinical decision-making, suggesting the product is better suited for managing the symptoms of the disease rather than the pain from its surgical treatment.

Table 3: Summary of Key Clinical Trials for Policresulen/Dibucaine Hydrochloride
Study (Reference)	Study Design	Patient Population & Size (n)	Intervention(s)	Primary Outcome(s)	Key Findings/Conclusion	Source Snippet(s)
Espinosa DJ (2000)	Meta-analysis of 7 multicenter studies	Patients with hemorrhoid pathology (n=2287)	Policresulen/Cinchocaine ointment and/or suppositories	Therapeutic efficacy and tolerability rated by physicians and patients	Highly satisfactory results in >82% of patients. Effective for bleeding hemorrhoids, fissures, pruritus, and post-op wound care.	23
Froehner Junior I, et al. (2014)	Prospective, double-blinded, placebo-controlled trial	Patients undergoing open hemorrhoidectomy (n=43)	1. Policresulen/Cinchocaine ointment 2. Placebo ointment 3. Control (oral meds only)	Pain intensity measured by Visual Analogue Scale (VAS) at multiple time points post-op	No statistically significant difference in pain scores between groups at any time point. Concluded no reduction in pain after hemorrhoidectomy.	26

5.0 Comprehensive Safety and Tolerability Profile

5.1 Adverse Drug Reactions and Side Effects

The combination product is generally well-tolerated, with most adverse effects being localized and transient.

• Combination Product (e.g., Faktu): The most frequently reported side effects are application site reactions, such as a sensation of burning, itching (pruritus), or general discomfort.[1] These symptoms are often mild, occur at the beginning of treatment, and are considered to be associated with the therapeutic mechanism of Policresulen's high acidity. They typically resolve quickly without requiring discontinuation of the medication.[2] In very rare instances, hypersensitivity reactions may occur, ranging from allergic contact dermatitis (presenting as redness and papules) to systemic allergic reactions like angioedema, urticaria, or anaphylaxis.[2]
• Dibucaine (Monotherapy): As a single agent, Dibucaine can cause contact dermatitis and photosensitivity.[44] While systemic absorption from proper topical use is low, it is not negligible. If significant absorption occurs, serious systemic adverse events can manifest, including headache, cyanosis (due to methemoglobinemia), cardiac arrhythmias, seizures, and respiratory depression.[51]

5.2 Contraindications, Warnings, and Precautions

Strict adherence to warnings and contraindications is essential to ensure the safe use of this combination product.

• Contraindications: The primary contraindication is a known hypersensitivity to Policresulen, Dibucaine, other amide-type local anesthetics, or any of the formulation's excipients.[2] Certain formulations may contain soy-derived phospholipids, making them contraindicated for individuals with known allergies to soy or peanuts.[2] The use of Dibucaine-containing products is contraindicated in children under the age of 2 years.[42]
• Warnings and Precautions: The product is strictly for external use and must not be ingested.[51] Contact with the eyes, nose, and mouth should be avoided.[44] To minimize the risk of systemic absorption and associated toxicity, the product should not be applied over large surface areas or to open wounds, broken skin, or severely inflamed tissue.[44] Use is generally not recommended for prolonged periods (typically not exceeding 7 days without medical consultation).[42] Patients should be advised to discontinue use and consult a physician if their condition worsens, does not improve, or if rectal bleeding occurs.[44]

A noteworthy consideration is the potential for a synergistic increase in risk. The primary mechanism of Policresulen involves the chemical debridement and shedding of necrotic mucosal tissue.[9] This action inherently compromises the epithelial barrier. Damaged or broken skin is known to have significantly higher permeability to topical drugs compared to intact skin. Therefore, by disrupting the mucosal surface, Policresulen could theoretically facilitate greater systemic absorption of the co-formulated Dibucaine. This plausible pharmacodynamic interaction, while not explicitly documented in the provided materials, would amplify the primary safety concern associated with Dibucaine—systemic toxicity. This potential for increased absorption underscores the critical importance of adhering strictly to warnings regarding application area, duration of use, and contraindications for use on broken skin.

5.3 Use in Special Populations (Pregnancy, Lactation, Pediatrics)

Data on the use of this combination in special populations is limited, and caution is advised.

• Pregnancy: The use of Policresulen is generally contraindicated during the first trimester of pregnancy and should only be used thereafter if strictly indicated and after a careful risk-benefit assessment by a physician.[5] There are no adequate human studies for Dibucaine during pregnancy, and patients are advised to consult a healthcare professional before use.[44]
• Lactation: It is not known whether Policresulen or Dibucaine is excreted into human breast milk.[19] While topical Dibucaine is considered unlikely to pose a risk to a nursing infant if applied to areas away from the breast, it must never be applied to the nipple or areola due to the severe risk of toxicity (including seizures and cardiovascular collapse) if ingested by the infant.[62]
• Pediatrics: Dibucaine is contraindicated for use in children under 2 years of age.[42] In children over 2 years, the dosage and total amount applied in a 24-hour period must be strictly limited (e.g., no more than 7.5 g of a 1% ointment) to prevent systemic toxicity.[44]

5.4 Potential Drug Interactions

• Policresulen: To maintain its efficacy, which is dependent on its high acidity, Policresulen should not be used concurrently with other topical preparations in the same area, especially those that are alkaline. Such combinations could neutralize the Policresulen, reducing its effectiveness, or lead to unpredictable chemical reactions.[10]
• Dibucaine: If significant systemic absorption occurs, Dibucaine may interact with other medications. Caution is advised with concomitant use of other agents known to induce methemoglobinemia, such as nitrates, sulfonamides, and other local anesthetics, as the risk may be additive.[63] Similarly, if absorbed systemically, it could potentiate the effects of central nervous system (CNS) depressants like benzodiazepines or opioids.[64]

6.0 Regulatory Status and Global Availability

The regulatory approval and market availability of the Policresulen/Dibucaine hydrochloride combination product vary significantly across different regions.

6.1 International Brand Names and Formulations

The combination product is marketed globally under various brand names, with Faktu being the most prominent.[2] Other brand names for the combination, found primarily in Asian and South American markets, include Ebodyl, Hemor, Posuline, Proctoacid, Proctyl, and Soker.[66] Policresulen as a monotherapy is commonly known as Albothyl or Polilen, while Dibucaine monotherapy is marketed as Nupercainal in the United States.[9] A list of international brand names is provided in Table 4.

Table 4: International Brand Names for Policresulen/Dibucaine Hydrochloride Products
Brand Name	Active Ingredients	Country/Region	Source Snippet(s)
Faktu	Policresulen + Cinchocaine	Bosnia & Herzegowina, Brazil, Croatia, Czech Republic, Egypt, Hong Kong, India, Indonesia, Lebanon, Macedonia, Peru, Philippines, Portugal, Serbia, Taiwan	66
Ebodyl	Policresulen + Cinchocaine	Taiwan	66
Hemor	Policresulen + Cinchocaine	Ecuador	66
Policresuleno + Clor. Cinchocaína Medley	Policresulen + Cinchocaine	Brazil	66
Posuline	Policresulen + Cinchocaine	Taiwan	66
Proctoacid	Policresulen + Cinchocaine	Mexico	66
Proctyl	Policresulen + Cinchocaine	Argentina, Brazil	66
Soker	Policresulen + Cinchocaine	Taiwan	66

6.2 Regulatory Landscape: North America, Europe, and Australia

The global regulatory landscape for this combination product is notably divergent, reflecting differing national assessments of its risk-benefit profile.

• United States (FDA): In the U.S., Dibucaine is an approved over-the-counter (OTC) monograph drug for topical anesthetic use.[7] However, Policresulen has not received FDA approval. Product labeling for some Policresulen-containing products marketed under an unapproved drug status explicitly states they have not been found to be safe and effective by the FDA.[19] As a result, the combination product Faktu is not legally marketed in the United States.
• Europe (EMA): A search of the European Medicines Agency's (EMA) database for centrally authorized products does not yield an approval for Policresulen or the combination product.[69] This indicates that it has not undergone or passed the centralized authorization procedure for use across the entire European Union. Despite this, the product is available in several individual European member states, including Germany, Poland, Portugal, and Serbia, which signifies that it has been approved through national regulatory procedures in those countries.[66]
• Australia (TGA): A search of the Australian Register of Therapeutic Goods (ARTG) does not show a current registration for a combination product containing Policresulen and Dibucaine/Cinchocaine under the brand name Faktu or its active ingredients.[72] This suggests the product is not legally supplied in Australia.

This significant divergence in regulatory status—from being a prescription drug in some countries like the Philippines [81] to being available via national procedures in parts of Europe, yet completely unapproved in major markets like the US and Australia—points to differing conclusions on the product's risk-benefit profile by various national health authorities. This heterogeneity may be influenced by several factors, including the chemical complexity and characterization challenges of Policresulen, the conflicting clinical evidence on its efficacy, and the weight given to its long history of use in certain regions versus the stringent evidence-based requirements of others.

7.0 Conclusion and Expert Insights

7.1 Synthesis of the Therapeutic Profile

The combination of Policresulen and Dibucaine hydrochloride represents a multi-modal topical therapy designed for anorectal and gynecological conditions. The therapeutic rationale is compelling, as it pairs a potent local anesthetic for rapid relief of pain and itching with a unique chemical agent that provides a combination of antiseptic, hemostatic, and selective debriding actions to facilitate wound healing. This dual approach aims to manage both the acute symptoms and the underlying tissue pathology of conditions like hemorrhoids and anal fissures.

7.2 Gaps in Evidence and Future Research Directions

Despite its long history of use in many parts of the world, significant gaps in the clinical evidence base for this combination product remain. The most pressing issue is the conflicting data on its efficacy. The positive findings from a large meta-analysis of observational studies are directly contradicted by the negative results of a smaller but more rigorously designed randomized controlled trial for postoperative pain. This discrepancy highlights a critical need for further high-quality research. Future studies should focus on:

• Conducting large-scale, randomized, double-blind, placebo-controlled trials to definitively establish the efficacy of the combination product for specific, well-defined indications (e.g., symptomatic relief of Grade I/II hemorrhoids vs. postoperative pain).
• Investigating the pharmacokinetic profile of the combination, specifically to quantify the systemic absorption of Dibucaine when applied to mucosa that has been treated with Policresulen, to validate or refute the theoretical risk of increased absorption.
• Evaluating the long-term safety profile of the product, particularly with intermittent or prolonged use for chronic conditions.

7.3 Final Recommendations on Clinical Use

Based on the currently available evidence, the use of Policresulen/Dibucaine hydrochloride can be considered a reasonable option for the short-term symptomatic management of uncomplicated, non-surgical hemorrhoids and anal fissures. The evidence from large-scale observational use suggests a high degree of patient satisfaction in this context, likely due to the combination of rapid anesthetic relief and the hemostatic and cleansing effects of Policresulen.

However, its use as an analgesic following hemorrhoidectomy is not supported by the available high-quality clinical evidence and therefore cannot be recommended for this indication. Clinicians prescribing or recommending this product must remain vigilant regarding its contraindications and warnings. Patient education is paramount, particularly concerning the risks of systemic toxicity from Dibucaine if the product is overused or applied to large or broken areas of skin. The signs of both local hypersensitivity and systemic adverse events should be clearly communicated to the patient. Finally, the product's fragmented regulatory status necessitates that its use is guided by local availability and national health authority regulations.

Works cited

1. Policresulen + Dibucaine: View Uses, Side Effects and Medicines | 1mg, accessed October 4, 2025, https://www.1mg.com/generics/policresulen-dibucaine-508892
2. faktu - BPOM, accessed October 4, 2025, https://registrasiobat.pom.go.id/files/assesment-reports/01702451198.pdf
3. Faktu Rectal Ointment: View Uses, Side Effects, Price and Substitutes | 1mg, accessed October 4, 2025, https://www.1mg.com/drugs/faktu-rectal-ointment-855270
4. www.1mg.com, accessed October 4, 2025, https://www.1mg.com/drugs/faktu-rectal-ointment-855270#:~:text=Faktu%20Rectal%20Ointment%20is%20a,or%20around%20the%20anal%20region.
5. Faktu: Package Leaflet: Information For The User | PDF | Topical Medication - Scribd, accessed October 4, 2025, https://www.scribd.com/document/564767449/Faktu-ointment
6. Faktu Rectal Ointment and Suppositories: Patient Information | Policy Commons, accessed October 4, 2025, https://policycommons.net/artifacts/14527489/pribalova-informace/15427407/
7. Dibucaine (topical application route) - Side effects & dosage - Mayo Clinic, accessed October 4, 2025, https://www.mayoclinic.org/drugs-supplements/dibucaine-topical-application-route/description/drg-20072892
8. Dibucaine 1% Topical Ointment: A Detailed Clinical Profile - GlobalRx, accessed October 4, 2025, https://www.globalrx.com/articles?article=dibucaine-1-percent-ointment-profile&product_id=124107
9. Policresulen - Wikipedia, accessed October 4, 2025, https://en.wikipedia.org/wiki/Policresulen
10. What is Policresulen used for? - Patsnap Synapse, accessed October 4, 2025, https://synapse.patsnap.com/article/what-is-policresulen-used-for
11. What is the mechanism of Policresulen? - Patsnap Synapse, accessed October 4, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-policresulen
12. en.wikipedia.org, accessed October 4, 2025, https://en.wikipedia.org/wiki/Sulfonic_acid
13. SAFETY DATA SHEET Policresulen Formulation - Merck.com, accessed October 4, 2025, https://www.merck.com/docs/product/safety-data-sheets/ah-sds/Policresulen%20Formulation_AH_US_EN.pdf
14. Policresulen Formulation - Merck.com, accessed October 4, 2025, https://www.merck.com/docs/product/safety-data-sheets/ah-sds/Policresulen%20Formulation_AH_BR_EN.pdf
15. Policresulen Formulation - MSD, accessed October 4, 2025, https://www.msd.com/docs/product/safety-data-sheets/ah-sds/Policresulen%20Formulation_AH_ZA_6N.pdf
16. Policresulen - 50% aqueous | 101418-00-2 | FP41112 - Biosynth, accessed October 4, 2025, https://www.biosynth.com/p/FP41112/101418-00-2-policresulen-50-aqueous
17. Policresulen | CAS#:101418-00-2 | Chemsrc, accessed October 4, 2025, https://www.chemsrc.com/en/cas/101418-00-2_166302.html
18. Policresulen - Safety Data Sheet - ChemicalBook, accessed October 4, 2025, https://www.chemicalbook.com/msds/policresulen.htm
19. policresulen | Dosing & Uses - medtigo, accessed October 4, 2025, https://medtigo.com/drug/policresulen/
20. Label: JUJIAFENHUANGQUAN YINDAOSHUAN- policresulen vaginal suppository suppository - DailyMed, accessed October 4, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13040102-aed4-9cb4-e063-6394a90a41bb&audience=consumer
21. Drug Approvals and Databases | FDA, accessed October 4, 2025, https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases
22. Policresulen, accessed October 4, 2025, http://medbox.iiab.me/kiwix/wikipedia_en_medicine_2019-12/A/Policresulen
23. [Analytical review of multicenter studies with polycresulene for ..., accessed October 4, 2025, https://pubmed.ncbi.nlm.nih.gov/10975023/
24. dailymed.nlm.nih.gov, accessed October 4, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=12364bc4-1328-03d6-e063-6294a90a302b&type=display
25. What is Policresulen and Used for? - MuseChem, accessed October 4, 2025, https://www.musechem.com/blog/what-is-policresulen-and-used-for/
26. (PDF) Postoperative topical analgesia of hemorrhoidectomy with ..., accessed October 4, 2025, https://www.researchgate.net/publication/263056071_Postoperative_topical_analgesia_of_hemorrhoidectomy_with_policresulen_and_cinchocaine_A_prospective_and_controlled_study
27. What are the side effects of Policresulen? - Patsnap Synapse, accessed October 4, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-policresulen
28. Uses of Albothyl medicine - Vinmec, accessed October 4, 2025, https://www.vinmec.com/eng/blog/uses-of-albothyl-en
29. Translation from German SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Albothyl® concentrate, 36%, vaginal - Acino, accessed October 4, 2025, https://acino.com.sa/wp-content/uploads/2022/02/sa-spc.pdf
30. Suppositories in anal disorders: A review - ResearchGate, accessed October 4, 2025, https://www.researchgate.net/publication/5876545_Suppositories_in_anal_disorders_A_review
31. Dibucaine, accessed October 4, 2025, https://www.drugfuture.com/chemdata/dibucaine.html
32. Dibucaine Hydrochloride 61-12-1 | Tokyo Chemical Industry (India ..., accessed October 4, 2025, https://www.tcichemicals.com/IN/en/p/B6467
33. Dibucaine hydrochloride | Fisher Scientific, accessed October 4, 2025, https://www.fishersci.ca/shop/products/dibucaine-hydrochloride-thermo-scientific/p-7042514
34. Dibucaine Hydrochloride - OrlandoSkinDoc |, accessed October 4, 2025, https://orlandoskindoc.com/dibucaine-hydrochloride/
35. Cinchocaine - Wikipedia, accessed October 4, 2025, https://en.wikipedia.org/wiki/Cinchocaine
36. KEGG DRUG: Dibucaine hydrochloride, accessed October 4, 2025, https://www.genome.jp/dbget-bin/www_bget?dr:D02220
37. Dibucaine analytical standard, = 99 61-12-1 - Sigma-Aldrich, accessed October 4, 2025, https://www.sigmaaldrich.com/US/en/product/sial/d0638
38. Cinchocaine hydrochloride | DrugBank Online, accessed October 4, 2025, https://go.drugbank.com/salts/DBSALT000639
39. Dibucaine hydrochloride | 61-12-1 - ChemicalBook, accessed October 4, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8358372.htm
40. Dibucaine | C20H29N3O2 | CID 3025 - PubChem, accessed October 4, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Dibucaine
41. dibucaine | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 4, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7159
42. Dibucaine (Nupercainal): Uses, Side Effects, Dosage & Reviews - GoodRx, accessed October 4, 2025, https://www.goodrx.com/dibucaine/what-is
43. Dibucaine | CaMK | Sodium Channel | AChR - TargetMol, accessed October 4, 2025, https://www.targetmol.com/compound/dibucaine
44. Indication-specific dosing for Nupercainal (dibucaine topical ..., accessed October 4, 2025, https://reference.medscape.com/drug/nupercainal-dibucaine-topical-ointment-999416
45. Cinchocaine hydrochloride determination by atomic spectrometry and spectrophotometry | Request PDF - ResearchGate, accessed October 4, 2025, https://www.researchgate.net/publication/7830470_Cinchocaine_hydrochloride_determination_by_atomic_spectrometry_and_spectrophotometry
46. Dibucaine - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Hepatic Dose | Drug Index | Pediatric Oncall, accessed October 4, 2025, https://www.pediatriconcall.com/drugs/dibucaine/484
47. Dibucaine hydrochloride (Cinchocaine hydrochloride) | Sodium Channel Inhibitor, accessed October 4, 2025, https://www.medchemexpress.com/Dibucaine-hydrochloride.html
48. Dibucaine HCl | Sodium Channel inhibitor | Mechanism | Concentration - Selleck Chemicals, accessed October 4, 2025, https://www.selleckchem.com/products/dibucaine-cinchocaine-hcl.html
49. Label: DIBUCAINE ointment - DailyMed, accessed October 4, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ae5992a-c544-4fd8-93f8-0f97c653203c
50. Dibucaine | Memorial Sloan Kettering Cancer Center, accessed October 4, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/dibucaine?mode=large&msk_tools_print=pdf
51. dibucaine topical, accessed October 4, 2025, https://www.myactivehealth.com/hwcontent/content/multum/d01301a1.html
52. Dibucaine - brand name list from Drugs.com, accessed October 4, 2025, https://www.drugs.com/ingredient/dibucaine.html
53. Policresulen: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed October 4, 2025, https://go.drugbank.com/drugs/DB13492
54. FAKTU, Policresulen + Cinchocaine Hydrochloride Ointment 20g [PRESCRIPTION REQUIRED] | Watsons Philippines, accessed October 4, 2025, https://www.watsons.com.ph/faktu-policresulen-cinchocaine-hydrochloride-ointment-20g-prescription-required/p/BP_10002132
55. lIIllIlIIII lIIllIlIIII, accessed October 4, 2025, http://shijiebiaopin.net/upload/product/201271700163227.PDF
56. Faktu (Policresulen + Cinchocaine) Suppository - eHealthPlus, accessed October 4, 2025, https://ehealthplusph.com/product/faktu-policresulen-cinchocaine-suppository/
57. a prospective and controlled study Postoperative topical analgesia of hemorrhoidectomy with policresulen and cinchocaine - SciELO, accessed October 4, 2025, https://www.scielo.br/j/rcbc/a/x9sqt7fRfCtTmyTfsj3Ss7z/
58. Postoperative topical analgesia of hemorrhoidectomy with policresulen and cinchocaine: a prospective and controlled study - SciELO, accessed October 4, 2025, https://www.scielo.br/j/rcbc/a/x9sqt7fRfCtTmyTfsj3Ss7z/?lang=en&format=pdf
59. Postoperative topical analgesia of hemorrhoidectomy with policresulen and cinchocaine: a prospective and controlled study - PubMed, accessed October 4, 2025, https://pubmed.ncbi.nlm.nih.gov/24918721/
60. Dibucaine | Memorial Sloan Kettering Cancer Center, accessed October 4, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/dibucaine?msk_tools_print=pdf
61. Dibucaine Topical Ointment: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed October 4, 2025, https://www.rxlist.com/dibucaine_topical_ointment/generic-drug.htm
62. Dibucaine - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed October 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK501754/
63. Drug Interaction Report: dibucaine topical, Percocet 10/325, accessed October 4, 2025, https://www.drugs.com/interactions-check.php?drug_list=864-0,72-8506&professional=1
64. Dibucaine topical and Multi-Symptom Nighttime Interactions - Drugs.com, accessed October 4, 2025, https://www.drugs.com/drug-interactions/dibucaine-topical-with-multi-symptom-nighttime-864-0-55-15928.html?professional=1
65. Cinchocaine: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed October 4, 2025, https://go.drugbank.com/drugs/DB00527
66. Policresulen (International database) - Drugs.com, accessed October 4, 2025, https://www.drugs.com/international/policresulen.html
67. Dibucaine | FDA Orange Book | Approved Drug Product List - PharmaCompass.com, accessed October 4, 2025, https://www.pharmacompass.com/fda-orange-book/dibucaine
68. Label: ALBOTHYL- policresulen solution solution - DailyMed, accessed October 4, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=847dca04-cfe6-19be-e053-2991aa0a04df
69. European Medicines Agency (EMA), accessed October 4, 2025, https://www.ema.europa.eu/en/medicines
70. Search | European Medicines Agency (EMA), accessed October 4, 2025, https://www.ema.europa.eu/en/search
71. FAKTU lind Hämorrhoidenzäpfchen 10 Pcs - Arzneiprivat, accessed October 4, 2025, https://www.arzneiprivat.de/product/faktu-lind-haemorrhoidenzaepfchen.989459?language_code=en
72. Australian Register of Therapeutic Goods (ARTG), accessed October 4, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
73. Therapeutic Goods Administration (TGA) | Australian Government Department of Health, Disability and Ageing, accessed October 4, 2025, https://www.tga.gov.au/
74. Medicines | Therapeutic Goods Administration (TGA), accessed October 4, 2025, https://www.tga.gov.au/products/medicines
75. Searching the Australian Register of Therapeutic Goods (ARTG), accessed October 4, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg
76. ARTG Search Visualisation Tool - the Regulatory and Compliance Portal., accessed October 4, 2025, https://compliance.health.gov.au/artg/
77. TGA – Therapeutic Goods Administration - Healthdirect, accessed October 4, 2025, https://www.healthdirect.gov.au/partners/tga-therapeutic-goods-administration
78. Therapeutic Goods Administration - Wikipedia, accessed October 4, 2025, https://en.wikipedia.org/wiki/Therapeutic_Goods_Administration
79. What is TGA Australia? Why Products Need It - Helix Solutions, accessed October 4, 2025, https://www.helixsolutions.net.au/news-and-resources/article/what-is-tga-australia-why-products-need-it
80. Therapeutic Goods Administration (TGA) - Department of Health, Disability and Ageing, accessed October 4, 2025, https://www.health.gov.au/contacts/therapeutic-goods-administration-tga
81. Human Drugs View - FDA Verification Portal, accessed October 4, 2025, https://verification.fda.gov.ph/drug_productsview.php?showdetail=®istration_number=DR-XY092